# Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

> **NCT04740827** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 315 (actual)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Atogepant 60 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04740827
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2022-08-04
- **Final completion:** 2022-08-04
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740827, "Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04740827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*